Skip to main content
. 2020 Aug 17;10(8):1613. doi: 10.3390/nano10081613

Figure 4.

Figure 4

Representative materials with acid-labile bond cleavage or degradation for cancer immunotherapy. (a) ALG = OVA: ovalbumin-conjugated alginate; (b) GDR: galactosyl dextran-retinal conjugates; (c) CART D13:A11: charge-altering releasable transporter with 13 carbonate repeating units and 11 amino ester repeating units; (d) PEG2000-hydrazone-C18: conjugates of polyethylene glycol (molecular weight of 2000) and stearic hydrazide; (e) PEG-CDM-PDEA: conjugates of PEG and poly(2-(diethylamino) ethyl methacrylate with 2-propionic-3-methylmaleic anhydride linkers; (f) DiPt-ASlink-PEG2k: conjugates of PEG2000 and hexadecyl-oxaliplatin(IV) with 2-propionic-3-methylmaleic anhydride linkers; (g) PEG = TMC-Man: PEG and mannose doubly modified trimethyl chitosan; PAH-Cit (PC): citraconic anhydride-grafted poly (allylamine hydrochloride); (h) HA-ADH-DOX: conjugates of hyaluronic acid and doxorubicin with hydrazine linkers; (i) PLGA: poly(lactic-co-glycolic acid); (j) PLGA-NaHCO3/NH4HCO3 NP: NaHCO3 or NH4HCO3-encapsulated PLGA nanoparticle; and (k) MOF: Metal-organic framework. The acid-labile groups are indicated in red.